Laboratory Products

  • AI-enabled Precision Medicine Platform Identifies 68 Genes Associated with High Risk of Severe COVID-19

AI-enabled Precision Medicine Platform Identifies 68 Genes Associated with High Risk of Severe COVID-19

Jul 03 2020 Read 787 Times

Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyse the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2. See results on the pre-publication site, medRxiv

Prior to an effective and widely available vaccine, PrecisionLife’s insights may help to identify patients who are at greatest risk of developing the most severe forms of COVID-19. They can inform the development of biomarker driven tests, targeted shielding and new therapeutic strategies, with the aim of identifying high-risk people, reducing disease burden and improving survival rates.

Established Genome Wide Association Studies (GWAS) approaches have been limited by the heterogenous nature of COVID-19, making it difficult to clearly explain the wide range of symptoms and impacts of predisposing comorbidities associated with the disease. The study has overcome this barrier by evaluating combinations of genetic features, which is not possible with existing GWAS approaches. 

Using a combinatorial (high-order epistasis) analysis approach, PrecisionLife identified 68 protein-coding genes that were highly associated with severe COVID-19, nine of which have been previously linked to differential response to SARS-CoV-2. These 68 genes include several druggable protein targets and pathways, nine of which are targeted by drugs that have reached at least Phase I clinical trials. 

"This is our second study specifically looking at host genomics to identify those most at risk and find opportunities to treat patients with later stage severe disease where host immune processes begin to run out of control," said Dr Steve Gardner, CEO of PrecisionLife.

"We know that systemic remodelling, leaky vasculature and micro-clotting can cause severe issues in COVID-19 patients in lungs as well as other organs. We are encouraged that several of the genes identified relate to lipid programming, beta-catenin and protein kinase C signalling whose processes converge in a central pathway involved in plasma membrane repair, clotting and wound healing. This pathway is largely driven by calcium ion activation, which is a known serum biomarker associated with severe COVID-19 and ARDS. We intend to perform further analyses to investigate this hypothesis. We are also seeking to further validate 12 genes associated with dysfunctional immune response that are the first hint at a potential genetic signature for enhanced risk of flipping into a severe disease state." 

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Lab Asia August 2020

August 2020

In This Edition Chromatography - Measurement of Pesticides in Cannabis sativa and Hemp Matrices - Biphenyl Modified Silica Stabilised by Bulky Substituents - Wettable Phase for Analytical a...

View all digital editions

Events

SIAF Guangzhou - NEW DATES

Aug 11 2020 Guanghzou, China

IE Expo China 2020 - NEW DATES

Aug 13 2020 Shanghai, China

ACS National Meeting & Expo, Fall 2020

Aug 16 2020 San Francisco, CA, USA

Chemspec India 2020 - CANCELLED

Aug 19 2020 Mumbai, India

View all events